These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 2721574

  • 1. Effects of ONO-3708, an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on platelet aggregation and thrombosis.
    Kondo K, Seo R, Naka M, Kitagawa T, Wakitani K, Sakata M, Kira H, Okegawa T, Kawasaki A.
    Eur J Pharmacol; 1989 Apr 25; 163(2-3):253-61. PubMed ID: 2721574
    [Abstract] [Full Text] [Related]

  • 2. Effects of ONO-3708, an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on blood vessels.
    Kondo K, Seo R, Omawari N, Imawaka H, Wakitani K, Kira H, Okegawa T, Kawasaki A.
    Eur J Pharmacol; 1989 Sep 13; 168(2):193-200. PubMed ID: 2606148
    [Abstract] [Full Text] [Related]

  • 3. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS, Johns A, Kleha J, Xie J, Wang Y, Bianchi J, Conley K.
    J Pharmacol Exp Ther; 1994 Mar 13; 268(3):1352-61. PubMed ID: 8138950
    [Abstract] [Full Text] [Related]

  • 4. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
    Fitzgerald DJ, Doran J, Jackson E, FitzGerald GA.
    J Clin Invest; 1986 Feb 13; 77(2):496-502. PubMed ID: 3003161
    [Abstract] [Full Text] [Related]

  • 5. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 2000 Jan 13; 292(1):238-46. PubMed ID: 10604953
    [Abstract] [Full Text] [Related]

  • 6. Protective effects of ONO 3708, a new thromboxane A2 receptor antagonist, during experimental endotoxin shock.
    Taneyama C, Sasao J, Senna S, Kimura M, Kiyono S, Goto H, Arakawa K.
    Circ Shock; 1989 May 13; 28(1):69-77. PubMed ID: 2525079
    [Abstract] [Full Text] [Related]

  • 7. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
    Mais DE, Saussy DL, Chaikhouni A, Kochel PJ, Knapp DR, Hamanaka N, Halushka PV.
    J Pharmacol Exp Ther; 1985 May 13; 233(2):418-24. PubMed ID: 2987481
    [Abstract] [Full Text] [Related]

  • 8. [Effect of a new thromboxane A2 antagonist, S-145, on platelet aggregation].
    Kakushi H, Shike T, Uchida K.
    Nihon Yakurigaku Zasshi; 1989 Mar 13; 93(3):171-8. PubMed ID: 2731807
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists.
    Ashton JH, Schmitz JM, Campbell WB, Ogletree ML, Raheja S, Taylor AL, Fitzgerald C, Buja LM, Willerson JT.
    Circ Res; 1986 Nov 13; 59(5):568-78. PubMed ID: 3542279
    [Abstract] [Full Text] [Related]

  • 10. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo.
    Ogletree ML, Harris DN, Heran CL, Phillips MB, Michel IM, Goldenberg HJ.
    Eicosanoids; 1988 Nov 13; 1(2):85-91. PubMed ID: 2856188
    [Abstract] [Full Text] [Related]

  • 11. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P, Rosolowsky M, Yao SK, McNatt J, De Clerck F, Buja LM, Willerson JT.
    J Clin Invest; 1990 Oct 13; 86(4):1095-102. PubMed ID: 2145320
    [Abstract] [Full Text] [Related]

  • 12. Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species.
    Narumiya S, Okuma M, Ushikubi F.
    Br J Pharmacol; 1986 Jun 13; 88(2):323-31. PubMed ID: 3730697
    [Abstract] [Full Text] [Related]

  • 13. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD.
    J Pharmacol Exp Ther; 1993 Sep 13; 266(3):1501-11. PubMed ID: 8371153
    [Abstract] [Full Text] [Related]

  • 14. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.
    Yao SK, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand JP, Campbell WB, Buja LM.
    Circ Res; 1992 Jan 13; 70(1):39-48. PubMed ID: 1727687
    [Abstract] [Full Text] [Related]

  • 15. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.
    Naka M, Mais DE, Morinelli TA, Hamanaka N, Oatis JE, Halushka PV.
    J Pharmacol Exp Ther; 1992 Aug 13; 262(2):632-7. PubMed ID: 1386885
    [Abstract] [Full Text] [Related]

  • 16. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K, Halushka PV, Yan YT, Wong PY.
    J Pharmacol Exp Ther; 1994 Sep 13; 270(3):1192-6. PubMed ID: 7932171
    [Abstract] [Full Text] [Related]

  • 17. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
    Bertolino F, Valentin JP, Maffre M, Grelac F, Bessac AM, Maclouf J, Delhon A, Lévy-Toledano S, Patoiseau JF, Colpaert FC.
    Br J Pharmacol; 1995 May 13; 115(1):210-6. PubMed ID: 7647979
    [Abstract] [Full Text] [Related]

  • 18. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
    Ohkubo S, Nakahata N, Ohizumi Y.
    Br J Pharmacol; 1996 Mar 13; 117(6):1095-104. PubMed ID: 8882602
    [Abstract] [Full Text] [Related]

  • 19. Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs.
    Maalej N, Osman HE, Shanmuganayagam D, Shebuski RJ, Folts JD.
    J Cardiovasc Pharmacol; 2005 May 13; 45(5):389-95. PubMed ID: 15821433
    [Abstract] [Full Text] [Related]

  • 20. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA, Batey AJ, Coker SJ.
    Br J Pharmacol; 1997 Jul 13; 121(5):875-82. PubMed ID: 9222543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.